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External validation studies of prediction models are of utmost impor-
tance in order to assess the performance of a predictionmodel in different
locations (Altman et al., 2009).We therefore readwith interest the recent
external validation study of the ADNEX model (Szubert et al., 2016).
For patients with a persistent adnexal tumor who are scheduled for
surgery, the ADNEXmodel predicts the risk of ﬁve tumor types: benign,
borderline malignant, stage I cancer, stage II–IV cancer, or secondary
metastatic cancer (Van Calster et al., 2014). The model was developed
on data from 5909 patients collected at 24 centers, in 10 countries, be-
tween 1999 and 2012. ADNEX aims to assist cliniciansmake appropriate
clinical decisions for patients presenting with an adnexal mass. When
validating the ADNEXmodel, it is natural to ﬁrst evaluate the prediction
ofmalignancy, followed by themulticlass prediction ofmalignancy sub-
types, in a similar way to other validation studies of multiclass models
(Steyerberg et al., 1998). This approach is followed in the recent
paper, but there are a number of important issues around the design,
analysis, and reporting we wish to raise.
First, validation studies should be designed to reliably assess perfor-
mance in terms of discrimination and calibration (Steyerberg, 2009). In
this particular case, the authors report a sample size calculation for test-
ing the hypothesis that the AUC of themodel is higher than 0.5. Assum-
ing an AUC of 0.94 leads to a very low required sample size (n = 22).
This approach is at odds with methodological guidance and the result
is that the precision of performance measures will be low: for dichoto-
mous prediction, previous studies have suggested that at least 100,
and preferably at least 200 individuals with the event (in this case ovar-
ian malignancy) are required for a meaningful validation (Steyerberg,
2009; Vergouwe et al., 2005; Collins et al., 2016). Here, center 1 has
70 malignant tumors, whilst center 2 has only 34, leading to unreliable
per center results. Validation would therefore best be done on all pa-
tients, with center-speciﬁc results as an exploratory addition. Further-
more, statistical tests to compare results between centers are provided
throughout the text. Although heterogeneity of performance across lo-
cations is important (Riley et al., 2016), p-values to compare two specif-
ic centers are uninformative. It is useful to observe that the AUCs were
0.955 and 0.907, since this is in line with the center-speciﬁc values
reported in the original publication describing the ADNEX model (Van
Calster et al., 2014). A detailed investigation of heterogeneity should
however involve a larger dataset with patients from many differentDOIs of original article: http://dx.doi.org/10.1016/j.gore.2016.10.009,
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very unreliable when stratiﬁed by center.
Second, the authors have not adequately described their population
and results. The prevalence of each of the ﬁve tumor types is not clearly
provided, and the prevalence of stage I cancer and stage II–IV cancer can
only be derived from the confusion matrix. The ADNEX model has var-
iants with and without the serummarker CA125 as a predictor. The au-
thors mix both variants depending on the availability of CA125, such
that it is unclear to what variant the reported performance is referring.
Third, the calibration of the predicted risk of malignancy has not
been investigated, i.e. whether observed frequencies of malignancy cor-
respond to predicted risks, especially around the risk threshold of 10%.
Unfortunately, this aspect of risk prediction models is often overlooked
despite its importance (Steyerberg, 2009).
Finally, the ‘multiclass’ performance evaluation is fundamentally
ﬂawed. The key problem is the confusion matrix, which classiﬁes pa-
tients into one of the ﬁve tumor types by choosing the group with the
highest predicted risk. Baseline risk, or prevalence, of each tumor type
varies substantially: among 327 patients, 223 are benign tumors
(68%), 16 borderline (5%), 14 stage I primary cancers (4%), 64 stage II–
IV primary cancers (20%), and 10 secondary metastatic cancers (3%).
Given these large differences in prevalence, it is unlikely that ADNEX
based risk predictions for secondary metastatic cancer will be larger
than those for a benign tumor. As a result, the confusion matrix will
rarely classify a tumor as ametastatic cancer, resulting in near zero sen-
sitivity for this tumor type. Analogous arguments apply to borderline tu-
mors and stage I primary cancers. Such results are misleading, since
they are unrelated to the model's ability to discriminate between
tumor types. More generally, it makes little clinical sense to classify pa-
tients into only one category. It is muchmore relevant tomonitorwhich
risks are high or increased, and to act upon them accordingly. For exam-
ple, the predicted risk of advanced-stage ovarian cancer and the risk of
secondary metastasis might both be increased (although the latter
will usually be smaller than the former due to the lower prevalence).
In such cases the clinician may focus management decisions on both
tumor types. An elevated risk of a metastatic tumor may trigger plan-
ning additional preoperative diagnostic tests, such as gastroscopy, x-
ray mammography or a full body MRI. Instead of a confusion matrix,
concordance or c statistics for subgroup discrimination should be
given. We would advise to present pairwise c statistics using the condi-
tional risk method (Van Calster et al., 2012, 2014), although other ap-
proaches could be followed. Nevertheless, we warn that in this study
the sample size is far too small to draw meaningful conclusions, al-
though we realize that it would require a very large sample to have in-
formation on 100 secondary metastatic cancers, as in the IOTA
collaboration (Van Calster et al., 2014).
In conclusion, we are happy to observe the excellent discrimination
between benign and malignant tumors seen in this study, in line with
the original publication (Van Calster et al., 2014). However, the analysis
does not allow us to draw any reliable conclusions with respect to
multiclass discrimination. To improve reporting of prediction modelthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
50 Correspondencestudies, the TRIPOD guidelines have recently been introduced (Moons
et al., 2015). These guidelines highlight the need for adequate sample
size, assessment of calibration and transparent reporting of key
information such as number of events in each category. Although we
recognize that validation of multiclass models involves additional difﬁ-
culties, it is clear that the TRIPOD recommendations should be followed
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